StockWireNews
Still Up Approx. 42%, (Nasdaq: ZVSA) Is A Low Float Profile Topping My Watchlist Currently
January 10th
Greetings Readers,
Continuing to surge green, ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) remains at the top spot on my watchlist Friday.
Here's the main reason why...
ZVSA is a low float profile.
With roughly 1.02Mn shares, its minuscule float could create an environment of extreme volatility in moments.
Now, at this moment, ZVSA is still up approx. 42% as we get closer to the bell.
That's after hitting a pre-market high of $2.26.
ZyVersa Therapeutics, Inc. (ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugs for patients with inflammatory or kidney diseases with high unmet medical needs.
They are well positioned in the rapidly emerging inflammasome space with a highly differentiated monoclonal antibody, Inflammasome ASC Inhibitor IC 100, and in kidney disease with phase 2 Cholesterol Efflux MediatorTM VAR 200.
The lead indication for IC 100 is obesity with metabolic complications, and for VAR 200, focal segmental glomerulosclerosis (FSGS).
Each therapeutic area offers a "pipeline within a product," with potential for numerous indications.
The total accessible market is over $100Bn.
Find key sources here: ZVSA Presentation.
-----
Coverage is officially initiated on ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA).
When more updates are available, I'll have them out quickly. Talk soon.
Sincerely,
Kai Parker
StockWireNews
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
No comments:
Post a Comment